Subcutaneous delivery of an anti-TNF inhibitor drug improved remission rates in patients with moderate-to-severe Crohn’s disease and ulcerative colitis, according to recent phase 3 clinical trial results published in the journal Gastroenterology.
Medical Xpress – latest medical and health news stories
Discover more from Nurse Unity Chats
Subscribe to get the latest posts sent to your email.
